Arrive AI (NASDAQ:ARAI) said it is expanding its commercial efforts in healthcare, manufacturing and specialty pharmacy delivery while preparing a new wave of its autonomous delivery infrastructure for shipment in September.
During its second-quarter earnings call, Chairman, CEO and Founder Dan O’Toole said the company expects to have more than a dozen AP3 Plus Arrive Points in inventory and ready to ship by mid-September. The units represent an expanded availability of the company’s secure delivery and pickup infrastructure and reflect progress in its supply chain, according to management.
Commercial Pipeline Focuses on Healthcare, Manufacturing
Ian Geise, Arrive AI’s head of commercialization, said the company is seeing its strongest commercial activity in healthcare, manufacturing and specialty pharmacy delivery.
In healthcare, Geise cited the company’s relationship with Nexus AMR, which is integrating Arrive AI products into its automation portfolio. He said Nexus AMR showcases the company’s technology at the TechNexus Innovation Center and has identified Arrive AI as a strategic partner.
Hancock Regional Hospital, described by the company as its anchor healthcare deployment, added another Arrive Point during the quarter. The additional unit enables building-to-building movement, which Geise said is an important capability for healthcare providers and large campus facilities.
In manufacturing, Arrive AI has partnered with DXC to introduce its technology into pharmaceutical manufacturing facilities with global operations. Geise said these sites can exceed 500,000 square feet and may require movement of products across campuses, including drone transport for longer distances. DXC’s systems-integration capabilities could help the company connect with enterprise customers more quickly, he said.
The company also has a letter of intent with LifeSpan Pharmacy and CarDon & Associates to explore an autonomous drone pharmacy-delivery program. Geise said Arrive AI is in early-stage discussions with several Fortune 500 companies regarding potential pharmaceutical-delivery opportunities.
Arrive AI is also in early discussions with autonomous delivery company Avride about potential pilot programs using the Arrive Point network. Geise noted that Avride became a continuity partner for university delivery operations following Starship Technologies’ exit from U.S. campus operations. Avride expects to operate on more than 20 campuses by year-end, but Arrive AI clarified during the question-and-answer session that those campuses do not represent existing Arrive Point deployments.
Product Roadmap Targets Expanded Capacity
Chief Operating Officer Mark Hamm said the AP3 Plus units scheduled for September will include the company’s new operating system and software, intended to allow customers and operators to monitor Arrive Points and their networks.
Arrive AI is developing its AP4 product, which management targets for the first quarter of 2027. Hamm said AP4 is expected to support multiple deliveries at once, simultaneous autonomous mobile robot pickup and drop-off, and drone deliveries. The associated supply chain is being designed to support hundreds of units during 2027, though Hamm said it remains uncertain whether the company will deploy that many units.
Management also discussed a subsequent product generation, referred to as APX or AP5, for which prototypes are expected at the end of next year. Hamm said its supply chain is being designed for thousands or tens of thousands of units and would offer greater capacity and more automated handoffs.
Second-Quarter Results and Funding Options
Arrive AI reported second-quarter revenue of $14,700, unchanged from the first quarter. The company said revenue increased slightly from a year earlier after excluding a nonrecurring consulting project included in the prior-year period.
- Second-quarter net loss was $14.1 million, compared with a $3.7 million net loss in the second quarter of 2025.
- The reported loss included $9.7 million in non-cash expenses tied to the conversion of outstanding notes.
- On a non-GAAP basis excluding those expenses, net loss was $4.3 million.
- Cash and liquid investments totaled $5.1 million at June 30, compared with $2.1 million in cash at Dec. 31.
- The company estimated its current cash burn rate at approximately $1.1 million per month.
O’Toole said Hancock Regional Hospital’s expansion is expected to generate incremental revenue in the third and fourth quarters. The company also filed an S-3 registration statement for up to $100 million and finalized terms for an at-the-market offering with capacity of about $15 million. Arrive AI additionally has $19 million in available future prepaid advances under its prior 2025 equity-line facility.
Addressing funding concerns, O’Toole said the company has financing options available and is managing operating and investment spending with attention to its balance sheet. He said the company is not at risk of running out of funds, while emphasizing that management is evaluating financing decisions strategically.
Patent Portfolio and International Plans
Corporate Counsel John Ritchison said Arrive AI has 10 issued U.S. patents and four additional U.S. patent applications pending. He said the company also has approximately 19 additional ideas moving through its development and intellectual-property process.
Internationally, Ritchison said the company has 13 issued patents, primarily in Asia, including India, Singapore, Australia and Japan, as well as patents in South Africa and Brazil. He said Arrive AI recently received approval for its first European Union patent and plans to examine licensing opportunities in Asia and Europe.
Ritchison also discussed a patent acquired through a strategic purchase involving a winch-based method intended to provide more controlled drone-package handling.
About Arrive AI (NASDAQ:ARAI)
We were incorporated on April 30, 2020, in the State of Delaware under the name of Dronedek Corporation. The Company changed its name to Arrive Technology Inc on July 27, 2023. The Company changed its name to Arrive AI Inc on September 30, 2024. We are a developmental technology company with a focus on designing and implementing a commercially viable smart mailbox and platform system for smart, secure, and seamless exchange of packages, goods, supplies, food, and medications between people, through the use of robots, and drones.
